Citigroup
ABCL icon

Citigroup’s AbCellera Biologics ABCL Stock Holding History

Citigroup’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-52,700
Closed -$1.06M – 5791
2021
Q3 		$1.06M Sell
52,700
-50,000
-49% -$884K ﹤0.01% 3041
2021
Q2 		$2.26M Buy
+102,700
New +$2.83M ﹤0.01% 2576

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Citigroup's ABCL Position: Q2 2026 in Review

Citigroup reduced its AbCellera Biologics (ABCL) stake by 15% in Q2 2026, selling an estimated $6.31K and leaving 7,182 shares worth $56.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4934.

Citigroup first reported a position in ABCL in Q1 2021 and has held it in 22 quarters since. The position peaked at $349K in Q2 2022. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Citigroup held 7,182 shares of AbCellera Biologics worth $56.4K as of Q2 2026.
  • Citigroup sold 1,290 AbCellera Biologics shares in Q2 2026, an estimated $6.31K.
  • AbCellera Biologics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4934 holding.
  • Citigroup first reported a position in AbCellera Biologics in Q1 2021 and has held it in 22 quarters since.
  • Citigroup's AbCellera Biologics position peaked at $349K in Q2 2022.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.